<DOC>
	<DOCNO>NCT01285167</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease ( COPD ) progressive largely irreversible lung disease characterize chronic bronchitis and/or emphysema , result breathlessness , cough sputum . As COPD progress , patient experience increase deterioration health-related quality life , great impairment ability work decline participation social physical activity . The aim non-interventional study evaluate data quality life COPD patient Germany real life medical set therapy phosphodiesterase-inhibitor ( PDE-4 ) roflumilast ( Daxas ) . Evaluation base two COPD specific questionnaire assess patient ` health status six month . During study , lung function measurement spirometry conduct accord common medical standard . Daxas ( tablet ) administer daily . The study provide data safety tolerability Daxas .</brief_summary>
	<brief_title>Quality Life Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease ( COPD ) ( DACOTA )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main severe COPD Main Child pugh ( classified B C )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Quality life</keyword>
	<keyword>lung function</keyword>
	<keyword>spirometry</keyword>
	<keyword>roflumilast</keyword>
	<keyword>Daxas</keyword>
	<keyword>severe COPD</keyword>
</DOC>